|1.||Goldberg, Richard M: 41 articles (04/2015 - 08/2002)|
|2.||de Gramont, Aimery: 39 articles (12/2015 - 04/2002)|
|3.||André, Thierry: 34 articles (12/2015 - 08/2002)|
|4.||Tabernero, Josep: 27 articles (12/2015 - 06/2004)|
|5.||Park, Young Suk: 27 articles (12/2015 - 07/2005)|
|6.||Saif, Muhammad Wasif: 26 articles (11/2015 - 01/2007)|
|7.||Van Cutsem, Eric: 24 articles (11/2015 - 04/2002)|
|8.||Lenz, Heinz-Josef: 24 articles (07/2013 - 06/2002)|
|9.||Louvet, Christophe: 23 articles (12/2015 - 08/2002)|
|10.||Grothey, Axel: 23 articles (10/2015 - 08/2003)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
08/23/2012 - "In contrast, oxaliplatin, containing the isomeric 1(R),2(R)-DACH carrier ligand, enjoys worldwide clinic application as a most important therapeutic agent in the treatment of colorectal cancer. "
10/01/2002 - "To date, oxaliplatin has proven to be a safe and effective therapy for colorectal cancer and side effects have been easy to manage with appropriate awareness from patients and care providers."
01/01/2004 - "Oxaliplatin combined with the bolus Nordic schedule of FU+FA (Nordic FLOX) is a well-tolerated, effective, and feasible bolus schedule as first-line treatment of metastatic colorectal cancer that yields comparable results compared with more complex schedules."
10/01/2003 - "Although no definitive data show one drug to be better than the other, several arguments favored the oxaliplatin/5-FU combination as a first-line treatment of metastatic colorectal cancer. "
01/01/2003 - "Oxaliplatin combined with the bolus Nordic schedule of 5-FU/ FA (Nordic FLOX) appears to be well tolerated, effective and feasible as first-line treatment of metastatic colorectal cancer yielding results comparable with those obtained by more complex schedules."
01/01/2010 - "In this experimental model, oxaliplatin was highly effective against intraperitoneal tumor spread but only with the intraperitoneal application route. "
10/01/2007 - "Anti-IGF-IR MoAB plus oxaliplatin led to a significantly greater inhibition of tumor growth. "
01/01/2014 - "Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin."
09/01/2012 - "Lipoxal also improved the specificity of oxaliplatin as shown by a higher ratio of tumor to right hemisphere uptake. "
02/01/2015 - "Oxaliplatin-based regimens are effective in metastasized advanced cancers. "
|3.||Stomach Neoplasms (Stomach Cancer)
06/01/2010 - "In conclusion, patients with at least one (105)Val allele have better prognosis and response to oxaliplatin/5-FU-based regimen as first-line treatment for patients with advanced gastric cancer."
11/01/2012 - "The combination of oxaliplatin and S-1 is effective in patients with advanced gastric cancer. "
09/01/2007 - "Oxaliplatin was reportedly effective for metastatic gastric cancer, but it is still non-approved in Japan. "
08/02/2004 - "This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. "
05/01/2010 - "These findings indicate that SOX regimen with oxaliplatin at a dose of 100 mg/m(2) is feasible and shows promising efficacy against advanced gastric cancer."
|4.||Colonic Neoplasms (Colon Cancer)
07/01/2009 - "CONCLUSION Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease."
06/01/2007 - "The addition of oxaliplatin to weekly FULV significantly improved DFS in patients with stage II and III colon cancer. "
11/01/2006 - "A review of the available evidence indicated that in patients with Stage III colon cancer, oxaliplatin in combination with an infusional de Gramont schedule of 5-FU/LV (FOLFOX4) was more effective in preventing and delaying disease recurrence than infusional 5-FU/LV alone (de Gramont regimen). "
11/01/2008 - "The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). "
11/01/2007 - "We therefore hypothesized that blocking oncogenic signaling with a Hsp90 inhibitor would impair metastatic behavior of colon cancer cells and also improve the efficacy of oxaliplatin in vivo. "
|5.||Neoplasm Metastasis (Metastasis)
06/01/1999 - "Promising results have been found in studies of the drug as monotherapy, and oxaliplatin may also prove useful in the neoadjuvant setting in patients with unresectable liver metastases; however, data are limited at present."
01/01/2010 - "In vivo, 50% of all rats given 10 mg/kg oxaliplatin 24 h before thermal therapy were completely immunologically cured, while a further 11% regressed their primary tumour but ultimately succumbed to metastases, and 17% experienced a limited response with increased survival. "
04/01/2006 - "This study evaluates the effect of topical application of oxaliplatin on the development of port-site metastases in an experimental murine model. "
10/01/2002 - "In a recent study in 389 such patients, 151 of which had liver-only metastases, 51% treated with oxaliplatin became resectable with some patients achieving a complete histologic response. "
04/01/2015 - "Patients with cT4 and lateral pelvic lymph node metastasis, and without distant metastasis (cM0), were treated with weekly oxaliplatin, oral S-1 40 mg/m(2) twice daily for 5 days a week, and radiation. "
|2.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)